{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:28Z","timestamp":1794047488182,"version":"4.8.0"},"reference-count":52,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) is a clonal plasma cell proliferative malignancy characterized by a debilitating bone disease. Osteolytic destruction, a hallmark of MM, is driven by increased osteoclast number and exacerbated bone resorption, primarily fueled by the excessive production of RANKL, the master regulator of osteoclast formation, within the tumor niche. We previously reported that osteocytes, the most abundant cells in the bone niche, promote tumor progression and support MM bone disease by overproducing RANKL. However, the molecular mechanisms underlying RANKL dysregulation in osteocytes in the context of MM bone disease are not entirely understood. Here, we present evidence that MM-derived CCL3 induces upregulation of RANKL expression in both human and murine osteocytes. Through a combination of in vitro, ex vivo, and in vivo models and clinical data, we demonstrate that genetic or pharmacologic inhibition of CCL3 prevents RANKL upregulation in osteocytes and attenuates the bone loss induced by MM cells. Mechanistic studies revealed that MM-derived CCL3 triggers the secretion of HMGB1 by osteocytes, a process required for osteocytic RANKL upregulation by MM cells. These findings identify a previously unknown CCL3-HMGB1 signaling axis in the MM tumor niche that drives bone resorption by promoting RANKL overproduction in osteocytes.<\/jats:p>","DOI":"10.3324\/haematol.2024.286484","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T14:43:55Z","timestamp":1732805035000},"page":"952-966","source":"Crossref","is-referenced-by-count":17,"title":["A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma"],"prefix":"10.3324","volume":"110","author":[{"given":"Aric","family":"Anloague","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley M.","family":"Sabol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Japneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Lowry","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Alturkmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ambrogini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Tveden","family":"Gundesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kristine","family":"Amstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Levin","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Diaz-delCastillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Delgado-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"74309","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95(5):548-567.","DOI":"10.1002\/ajh.25791"},{"key":"74310","doi-asserted-by":"crossref","unstructured":"Diaz-delCastillo M, Chantry AD, Lawson MA, Heegaard AM. Multiple myeloma - a painful disease of the bone marrow. Semin Cell Dev Biol. 2021; 112:49-58.","DOI":"10.1016\/j.semcdb.2020.10.006"},{"key":"74311","doi-asserted-by":"crossref","unstructured":"Horsboel TA, Nielsen CV, Andersen NT, Nielsen B, de Thurah A. Risk of disability pension for patients diagnosed with haematological malignancies: a register-based cohort study. Acta Oncol. 2014; 53(6):724-734.","DOI":"10.3109\/0284186X.2013.875625"},{"key":"74312","doi-asserted-by":"crossref","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009; 23(3):435-441.","DOI":"10.1038\/leu.2008.336"},{"key":"74313","doi-asserted-by":"crossref","unstructured":"Delgado-Calle J, Anderson J, Cregor MD. Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016; 76(5):1089-1100.","DOI":"10.1158\/0008-5472.CAN-15-1703"},{"key":"74314","doi-asserted-by":"crossref","unstructured":"Lai FP, Cole-Sinclair M, Cheng WJ. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol. 2004; 126(2):192-201.","DOI":"10.1111\/j.1365-2141.2004.05018.x"},{"key":"74315","doi-asserted-by":"crossref","unstructured":"Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O\u2019Brien CA. Matrix-embedded cells control osteoclast formation. Nat Med. 2011; 17(10):1235-1241.","DOI":"10.1038\/nm.2448"},{"key":"74316","doi-asserted-by":"crossref","unstructured":"Nakashima T, Hayashi M, Fukunaga T. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17(10):1231-1234.","DOI":"10.1038\/nm.2452"},{"key":"74317","doi-asserted-by":"crossref","unstructured":"Delgado-Calle J. Osteocytes and their messengers as targets for the treatment of multiple myeloma. Clin Rev Bone Miner Metab. 2017; 15(1):49-56.","DOI":"10.1007\/s12018-017-9227-7"},{"key":"74318","doi-asserted-by":"crossref","unstructured":"Toscani D, Bolzoni M, Ferretti M, Palumbo C, Giuliani N. Role of osteocytes in myeloma bone disease: anti-sclerostin antibody as new therapeutic strategy. Front Immunol. 2018; 24:9.","DOI":"10.3389\/fimmu.2018.02467"},{"key":"74319","doi-asserted-by":"crossref","unstructured":"Sabol HM, Ashby C, Adhikari M. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024; 109(8):2606-2618.","DOI":"10.3324\/haematol.2023.284443"},{"key":"74320","doi-asserted-by":"crossref","unstructured":"Sabol HM, Amorim T, Ashby C. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia. 2022; 28:100785.","DOI":"10.1016\/j.neo.2022.100785"},{"key":"74321","doi-asserted-by":"crossref","unstructured":"Sabol HM, Ferrari AJ, Adhikari M. Targeting Notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer Res. 2021; 81(19):5102-5114.","DOI":"10.1158\/0008-5472.CAN-21-0524"},{"key":"74322","doi-asserted-by":"crossref","unstructured":"Fu Q, Bustamante-Gomez NC, Reyes-Pardo H. Reduced OPG expression by osteocytes may contribute to rebound resorption after denosumab discontinuation. JCI Insight. 2023; 8(18):e167790.","DOI":"10.1172\/jci.insight.167790"},{"key":"74323","doi-asserted-by":"crossref","unstructured":"Simonet WS, Lacey DL, Dunstan CR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-319.","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"74324","doi-asserted-by":"crossref","unstructured":"Choi SJ, Cruz JC, Craig F. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000; 96(2):671-675.","DOI":"10.1182\/blood.V96.2.671"},{"key":"74325","doi-asserted-by":"crossref","unstructured":"Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001; 97(11):3349-3353.","DOI":"10.1182\/blood.V97.11.3349"},{"key":"74326","doi-asserted-by":"crossref","unstructured":"Vallet S, Pozzi S, Patel K. A novel role for CCL3 (MIP-1\u03b1) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia. 2011; 25(7):1174-1181.","DOI":"10.1038\/leu.2011.43"},{"key":"74327","doi-asserted-by":"crossref","unstructured":"Roussou M, Tasidou A, Dimopoulos MA. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia. 2009; 23(11):2177-2181.","DOI":"10.1038\/leu.2009.130"},{"key":"74328","doi-asserted-by":"crossref","unstructured":"Terpos E, Politou M, Viniou N, Rahemtulla A. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma. 2005; 46(12):1699-1707.","DOI":"10.1080\/10428190500175049"},{"key":"74329","doi-asserted-by":"crossref","unstructured":"Hashimoto T, Abe M, Oshima T. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004; 125(1):38-41.","DOI":"10.1111\/j.1365-2141.2004.04864.x"},{"key":"74330","doi-asserted-by":"crossref","unstructured":"Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 2003; 123(1):106-109.","DOI":"10.1046\/j.1365-2141.2003.04561.x"},{"key":"74331","doi-asserted-by":"crossref","unstructured":"Uneda S, Hata H, Matsuno F. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol. 2003; 120(1):53-55.","DOI":"10.1046\/j.1365-2141.2003.04040.x"},{"key":"74332","doi-asserted-by":"crossref","unstructured":"Bidwell JP, Yang J, Robling AG. Is HMGB1 an osteocyte alarmin?. J Cell Biochem. 2008; 103(6):1671-1680.","DOI":"10.1002\/jcb.21572"},{"key":"74333","doi-asserted-by":"crossref","unstructured":"Davis HM, Valdez S, Gomez L. High mobility group box 1 protein regulates osteoclastogenesis through direct actions on osteocytes and osteoclasts in vitro. J Cell Biochem. 2019; 120(10):16741-16749.","DOI":"10.1002\/jcb.28932"},{"key":"74334","doi-asserted-by":"crossref","unstructured":"Greipp PR, San Miguel J, Durie BG. International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-3420.","DOI":"10.1200\/JCO.2005.04.242"},{"key":"74335","doi-asserted-by":"crossref","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem. 2010; 109(2):283-291.","DOI":"10.1002\/jcb.22403"},{"key":"74336","doi-asserted-by":"crossref","unstructured":"Tsubaki M, Kato C, Isono A. Macrophage inflammatory protein-1\u03b1 induces osteoclast formation by activation of the MEK\/ERK\/c-Fos pathway and inhibition of the p38MAPK\/IRF-3\/ IFN-\u03b2 pathway. J Cell Biochem. 2010; 111(6):1661-1672.","DOI":"10.1002\/jcb.22907"},{"key":"74337","doi-asserted-by":"crossref","unstructured":"Oba Y, Lee JW, Ehrlich LA. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol. 2005; 33(3):272-278.","DOI":"10.1016\/j.exphem.2004.11.015"},{"key":"74338","doi-asserted-by":"crossref","unstructured":"Choi SJ, Oba Y, Gazitt Y. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001; 108(12):1833-1841.","DOI":"10.1172\/JCI13116"},{"key":"74339","doi-asserted-by":"crossref","unstructured":"Tsubaki M, Kato C, Manno M. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K\/ Akt pathways. Mol Cell Biochem. 2007; 304(1-2):53-60.","DOI":"10.1007\/s11010-007-9485-7"},{"key":"74340","doi-asserted-by":"crossref","unstructured":"Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood. 2001; 97(11):3349-3353.","DOI":"10.1182\/blood.V97.11.3349"},{"key":"74341","doi-asserted-by":"crossref","unstructured":"Toscani D, Palumbo C, Dalla PB. The proteasome inhibitor bortezomib maintains osteocyte viability in multiple myeloma patients by reducing both apoptosis and autophagy: a new function for proteasome inhibitors. J Bone Miner Res. 2016; 31(4):815-827.","DOI":"10.1002\/jbmr.2741"},{"key":"74342","doi-asserted-by":"crossref","unstructured":"Giuliani N, Ferretti M, Bolzoni M. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012; 26(6):1391-1401.","DOI":"10.1038\/leu.2011.381"},{"key":"74343","doi-asserted-by":"crossref","unstructured":"Davis HM, Pacheco-Costa R, Atkinson EG. Disruption of the Cx43\/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell. 2017; 16(3):551-563.","DOI":"10.1111\/acel.12586"},{"key":"74344","doi-asserted-by":"crossref","unstructured":"Geduk A, Oztas B, Ery\u0131lmaz BH. Effects of AGEs, sRAGE and HMGB1 on clinical outcomes in multiple myeloma. Indian J Hematol Blood Transfus. 2023; 39(2):220-227.","DOI":"10.1007\/s12288-022-01574-6"},{"key":"74345","doi-asserted-by":"crossref","unstructured":"Casciaro M, Vincelli D, Ferraro M. The role of high-mobility group box-1 and Psoriasin in multiple myeloma: analysis of a population affected by monoclonal gammopathies and review of the literature. Pathol Res Pract. 2023; 247:154562.","DOI":"10.1016\/j.prp.2023.154562"},{"key":"74346","doi-asserted-by":"crossref","unstructured":"Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med. 2022; 54(2):91-102.","DOI":"10.1038\/s12276-022-00736-w"},{"key":"74347","doi-asserted-by":"crossref","unstructured":"Liu H, He J, Bagheri-Yarmand R. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat Commun. 2022; 13(1):3684.","DOI":"10.1038\/s41467-022-31356-7"},{"key":"74348","doi-asserted-by":"crossref","unstructured":"Oyajobi BO, Franchin G, Williams PJ. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003; 102(1):311-319.","DOI":"10.1182\/blood-2002-12-3905"},{"key":"74349","doi-asserted-by":"crossref","unstructured":"Abe M, Hiura K, Ozaki S, Kido S, Matsumoto T. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab. 2009; 27(1):16-23.","DOI":"10.1007\/s00774-008-0012-z"},{"key":"74350","doi-asserted-by":"crossref","unstructured":"Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and benefits of bisphosphonate therapies. J Cell Biochem. 2016; 117(1):20-28.","DOI":"10.1002\/jcb.25266"},{"key":"74351","doi-asserted-by":"crossref","unstructured":"Aspenberg P, Schilcher J. Atypical femoral fractures, bisphosphonates, and mechanical stress. Curr Osteoporos Rep. 2014; 12(2):189-193.","DOI":"10.1007\/s11914-014-0200-9"},{"key":"74352","doi-asserted-by":"crossref","unstructured":"Raje N, Terpos E, Willenbacher W. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, doubledummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018; 19(3):370-381.","DOI":"10.1016\/S1470-2045(18)30072-X"},{"key":"74353","doi-asserted-by":"crossref","unstructured":"Drejer LA, El-Masri BM, Ejersted C. Trabecular bone deterioration in a postmenopausal female suffering multiple spontaneous vertebral fractures due to a delayed denosumab injection - a post-treatment re-initiation bone biopsy-based case study. Bone Rep. 2023; 19:101703.","DOI":"10.1016\/j.bonr.2023.101703"},{"key":"74354","doi-asserted-by":"crossref","unstructured":"Kim AS, Girgis CM, McDonald MM. Osteoclast recycling and the rebound phenomenon following denosumab discontinuation. Curr Osteoporos Rep. 2022; 20(6):505-515.","DOI":"10.1007\/s11914-022-00756-5"},{"key":"74355","doi-asserted-by":"crossref","unstructured":"Zeissig MN, Hewett DR, Mrozik KM. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines. Leuk Res. 2024; 139:107469.","DOI":"10.1016\/j.leukres.2024.107469"},{"key":"74356","doi-asserted-by":"crossref","unstructured":"Du J, Lin Z, Fu XH, Gu XR, Lu G, Hou J. Research progress of the chemokine\/chemokine receptor axes in the oncobiology of multiple myeloma (MM). Cell Commun Signal. 2024; 22(1):177.","DOI":"10.1186\/s12964-024-01544-7"},{"key":"74357","doi-asserted-by":"crossref","unstructured":"Liu L, Yu Z, Cheng H. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Sci Rep. 2020; 10(1):20508.","DOI":"10.1038\/s41598-020-77450-y"},{"key":"74358","doi-asserted-by":"crossref","unstructured":"Zeissig MN, Hewett DR, Panagopoulos V. Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica. 2021; 106(12):3176-3187.","DOI":"10.3324\/haematol.2020.253526"},{"key":"74359","doi-asserted-by":"crossref","unstructured":"Tsubaki M, Takeda T, Tomonari Y. The MIP-1\u03b1 autocrine loop contributes to decreased sensitivity to anticancer drugs. J Cell Physiol. 2018; 233(5):4258-4271.","DOI":"10.1002\/jcp.26245"},{"key":"74360","doi-asserted-by":"crossref","unstructured":"Dairaghi DJ, Oyajobi BO, Gupta A. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012; 120(7):1449-1457.","DOI":"10.1182\/blood-2011-10-384784"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11852\/77860","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11852\/78243","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11852\/77860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:42Z","timestamp":1794046062000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286484","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,28]]}}}